DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2271784/amprius-technologies-ampx-reports-q1-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2271784 May 09, 2024 - Amprius (AMPX) delivered earnings and revenue surprises of 0% and 37.41%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2271765/fate-therapeutics-fate-reports-q1-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2271765 May 09, 2024 - Fate Therapeutics (FATE) delivered earnings and revenue surprises of 0% and 140.63%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2271768/recursion-pharmaceuticals-rxrx-reports-q1-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2271768 May 09, 2024 - Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of 9.30% and 3.29%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2271769/array-technologies-inc-arry-tops-q1-earnings-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2271769 May 09, 2024 - Array Technologies (ARRY) delivered earnings and revenue surprises of 250% and 2.57%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2271771/cutera-cutr-reports-q1-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2271771 May 09, 2024 - Cutera (CUTR) delivered earnings and revenue surprises of 6.42% and 4.38%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2271770/oncternal-therapeutics-onct-reports-q1-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2271770 May 09, 2024 - Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 1.74% and 223.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2271772/gen-digital-gen-tops-q4-earnings-and-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2271772 May 09, 2024 - Gen Digital (GEN) delivered earnings and revenue surprises of 1.92% and 0.23%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2271758/quest-resource-qrhc-reports-q1-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2271758 May 09, 2024 - Quest Resource (QRHC) delivered earnings and revenue surprises of 50% and 0.49%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2271761/atara-biotherapeutics-atra-reports-q1-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2271761 May 09, 2024 - Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 37.84% and 1.32%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2271763/arcellx-inc-aclx-reports-q1-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2271763 May 09, 2024 - Arcellx (ACLX) delivered earnings and revenue surprises of 72.55% and 32.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock? 0